IPPRA / Grant Monitor

2026-07-07
← Board

DoW Duchenne Muscular Dystrophy, Idea Development Award

HT942526DMDRPIDA · Defense Health Agency Contracting Activity - DHACA

biomedical clinical public health education workforce Science & Technology R&D

Closes
2026-09-18 · 73 d
Award ceiling
Award floor
Program funding
$2,500,000
Expected awards
5
Cost sharing
No
Posted
2026-06-17
Instrument
Grant
Characterization · gpt-5.4-mini · 2026-07-07

Funds early-stage, high-risk/high-reward Duchenne muscular dystrophy research with testable hypotheses and preliminary data, for established or new independent investigators at eligible institutions.

Funds
applied research
University
direct
physical sciences
minor
engineering
minor
life biomedical
central
computational data
minor

⚑ Clinical trials and clinical-trial aims are not allowed. · Preliminary data relevant to DMD are required. · Three career categories are reviewed separately: Established Investigator, New Investigator–Early-Stage, and New Investigator–Transitioning.

Unit fits — one characterization, each unit's own rules

Physical Sciences & Engineering (demo) 55 good technical depth: minor; funds applied research
IPPRA 45 partial peripheral portfolio topic: public_health; social/behavioral work is none; funds applied research; biomedical core — IPPRA health lane is communication/crisis/policy (capped); capped at 45 (limited social-science role)
Tom Love Innovation Hub 30 weak funds applied research; deep-tech content

Description

Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.

Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:

• The Established Investigator category is for independent investigators at all academic levels, or equivalent

• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.

• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.

Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed.

Apply

View on Grants.gov → CONTACT: Danielle Reckley Grantor <help@eBRAP.org>

Proposal brief SEE AN EXAMPLE →

A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.

ONE LLM CALL (~1¢) · CACHED · REQUIRES STAFF KEY

Proposal shell · Department of Defense (BAA-style) conventions SEE A DOD EXAMPLE →

Funder-faithful document skeletons — Department of Defense (BAA-style)'s document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.

ONE LLM CALL (~2-3¢) · CACHED · SCAFFOLDING, NOT GHOSTWRITING